10.1021/jm8009316
The research details the rational design and synthesis of a novel nonsteroidal androgen receptor antagonist, PF-998425, intended for dermatological applications such as sebum control and treatment of androgenetic alopecia. The compound was designed to be potent, selective, and devoid of phototoxicity, a common issue with similar drugs. The study involved high-throughput screening using a [3H]DHT competitive ligand binding assay and MDA-MB-453-MMTV-luci cell line to identify active compounds. The synthesis of PF-998425 included a series of chemical reactions starting from 4-fluoro-2-(trifluoromethyl)benzonitrile and cyclohexanone, leading to the desired cis-alcohol (-)-6a with a key step being an asymmetric epoxidation using Jacobsen’s (S,S)Mn(III)-salen complex catalyst. The compound's activity was confirmed through in vitro assays, including binding assays and cellular functional assays, with IC50 values indicating potency. The compound's selectivity was tested against other nuclear hormone receptors, and its pharmacokinetics, in vivo activity, and safety were evaluated using various models and assays, including the 3T3 neutral red uptake (NRU) phototoxicity test, metabolic stability in rat liver microsomes, and pharmacokinetics in dogs. The results showed that PF-998425 was active in reducing sebum and stimulating hair growth without causing phototoxicity or significant systemic side effects, making it a promising candidate for topical dermatological treatments.